Under the finalized regulation, pharmacy benefit managers will be legally obligated to report all compensation received from drug manufacturers, brokers, and consulting firms to the employers that hire them. The transparency mandate forces middlemen to detail previously hidden revenue streams such as drug rebates, spread pricing, and potential conflicts of interest. The policy applies to more than 70 pharmacy benefit managers serving approximately 130,000 employers nationwide. These mandatory disclosures are officially slated to go into effect on July 1, 2027.
Key points
Employers will gain legal access to previously protected data covering drug rebates, spre…: Employers will gain legal access to previously protected data covering drug rebates, spread pricing, and consulting fees.
Pharmacy benefit managers must report external payments to reveal financial ties that may…: Pharmacy benefit managers must report external payments to reveal financial ties that may present conflicts of interest.
Enhanced transparency surrounding middleman compensation is projected to substantially re…: Enhanced transparency surrounding middleman compensation is projected to substantially reduce corporate and worker medication spending.
Sources checked by our analysis pipeline: 1
The middlemen that oversee prescription drug spending for employers and workers will soon have to tell their clients all the different ways they get paid, a significant move that will unlock reams of highly protected data.
The Trump administration finalized a regulation Thursday that will force pharmacy benefit managers to disclose all the different fees and compensation they get from drugmakers, consulting firms, and other entities to the employers that hire them. The disclosures — which will be required starting on July 1, 2027 — will include drug rebates, spread pricing, and financial relationships with brokers and consultants that could create conflicts of interest.
Federal officials estimate the rule will apply to more than 70 PBMs and 130,000 employers, saving more than $800 million annually through lower drug costs.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Critical digital booking platforms and consultation tools have gone dark across multiple regions, directly threatening mandatory access targets for primary care. The sudden vendor failure forces affected surgeries to revert to manual scheduling methods, adding immediate administrative strain to already stretched clinic staff. Medical leaders are urgently calling on health authorities to intervene and stabilize digital operations.
Industry professionals can engage with STAT journalists as the media outlet prepares to host an event at the upcoming HLTH conference in Las Vegas. The announcement arrived via the publication's dedicated technology newsletter, which covers the intersection of technological tools and the life sciences. Access to the associated coverage remains gated for premium members.